CD8A and non-small cell lung carcinoma: On the other hand, several studies examining circulating T cells have shown the involvement of CD8+ T cells, such as the proliferating (Ki67+) CD8+ effector-like T cells, in NSCLC patients receiving PD-1-therapy (52), and neoantigen-specific circulating CD8+ T cells in melanoma (53, 54).